| MA Credit Income Trust (MA1) ORDINARY UNITS FULLY PAID |
- |
$558 |
Dividend/Distribution - MA1
|
28 Jul 2025 10:17AM |
$2.040 |
$1.995 |
fallen by
2.21%
|
|
| Gold Mountain Limited (GMN) ORDINARY FULLY PAID |
Materials |
$23 |
Change of Director's Interest Notice on Consolidation x 3
|
28 Jul 2025 10:16AM |
$0.100 |
$0.078 |
fallen by
22%
|
|
| Moab Minerals Limited (MOM) ORDINARY FULLY PAID |
Materials |
$4 |
Quarterly Activities Report and Appendix 5B
|
28 Jul 2025 10:11AM |
$0.001 |
$0.002 |
risen by
100%
|
|
MOM - Price-sensitive ASX Announcement
Full Release
Key Points
- Quarterly Activities Report and Appendix 5B released for period ending 31 December 2023.
- Ongoing exploration and target generation at the Woodlands Project, Western Australia.
- Further geological mapping and soil sampling conducted.
- Assessment of lithium and critical minerals prospects continued.
- Appointment of new Managing Director announced.
- Appendix 5B summarises company’s cash flows, focusing on exploration and evaluation outflows.
- Company maintains stable financial position with adequate cash reserves.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Ventus Medical, Inc. (VNT2) ORDINARY FULLY PAID |
- |
- |
Webcast and Conference Call details for HY25 Results
|
28 Jul 2025 10:10AM |
n/a |
n/a |
n/a
|
|
| International Graphite Limited (IG6) ORDINARY FULLY PAID |
Industrials |
$11 |
Reinstatement to Quotation
|
28 Jul 2025 10:10AM |
$0.072 |
$0.041 |
fallen by
43.06%
|
|
IG6 - Price-sensitive ASX Announcement
Full Release
Key Points
- International Graphite Limited (IG6) has been reinstated to quotation on the ASX.
- The company operates graphite mining and processing projects in Western Australia.
- Reinstatement follows compliance with ASX listing rules and completion of capital raising.
- Funds raised will be used for project development, working capital, and exploration.
- Updates are provided on the Springdale Graphite Project and Collie downstream processing facility.
- The company remains committed to progressing its graphite business strategy.
- Board and management changes are detailed as part of ongoing corporate development.
- Recent financial activities and share structure updates are disclosed.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| International Graphite Limited (IG6) ORDINARY FULLY PAID |
Industrials |
$11 |
Agreement to develop new Expandable Graphite facility
|
28 Jul 2025 10:09AM |
$0.072 |
$0.041 |
fallen by
43.06%
|
|
IG6 - Price-sensitive ASX Announcement
Full Release
Key Points
- International Graphite Limited (IG6) and a Chinese industrial group have entered a non-binding agreement.
- The agreement is to develop and construct a new expandable graphite facility in Collie, Western Australia.
- Graphite feedstock will be sourced from IG6’s Springdale Graphite Project and processed at the Collie facility.
- The Chinese partner will contribute technology, design, and market access.
- The agreement supports IG6’s strategy to establish an integrated Australian graphite supply chain.
- Expandable graphite is a value-added product used in batteries and flame retardant applications.
- The partnership accelerates IG6’s timeline for entering the expandable graphite market.
- The facility aims to serve both domestic and international markets.
- The agreement remains subject to due diligence, definitive documentation, and regulatory approvals.
- Project supports Western Australia’s ambitions in critical minerals processing.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| International Graphite Limited (IG6) ORDINARY FULLY PAID |
Industrials |
$11 |
Comet share sale and debt repayment
|
28 Jul 2025 10:09AM |
$0.072 |
$0.041 |
fallen by
43.06%
|
|
IG6 - Price-sensitive ASX Announcement
Full Release
Key Points
- International Graphite Limited (IG6) sold 38,000,000 Comet Resources Limited shares.
- The gross proceeds from the sale total $570,000.
- Funds from the sale will be used to fully repay an outstanding loan.
- The debt repayment releases IG6 from previous debt obligations.
- IG6 retains a residual holding in Comet Resources Limited.
- The transaction improves IG6's balance sheet and financial flexibility.
- The company can now focus more on its core operations following the debt repayment.
- Details of the transaction background and rationale are provided.
- The announcement was made on June 13, 2024.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| wrkr Ltd (WRK) ORDINARY FULLY PAID |
Information Technology |
$179 |
Quarterly Update Presentation
|
28 Jul 2025 10:09AM |
$0.105 |
$0.090 |
fallen by
14.29%
|
|
| Bapcor Limited (BAP) ORDINARY FULLY PAID |
Consumer Discretionary |
$276 |
Appendix 3Z - J. Todd
|
28 Jul 2025 10:02AM |
$3.710 |
$0.410 |
fallen by
88.95%
|
|
| Bapcor Limited (BAP) ORDINARY FULLY PAID |
Consumer Discretionary |
$276 |
Appendix 3Z - B. Soller
|
28 Jul 2025 10:01AM |
$3.710 |
$0.410 |
fallen by
88.95%
|
|
| Bapcor Limited (BAP) ORDINARY FULLY PAID |
Consumer Discretionary |
$276 |
Appendix 3Z - M. Bernhard
|
28 Jul 2025 10:01AM |
$3.710 |
$0.410 |
fallen by
88.95%
|
|
| Peninsula Energy Limited (PEN) ORDINARY FULLY PAID |
Energy |
$223 |
Sales Contracts and Company Update
|
28 Jul 2025 10:00AM |
$0.620 |
$0.390 |
fallen by
37.10%
|
|
PEN - Price-sensitive ASX Announcement
Full Release
Key Points
- Sales contracts reset completed with mutual termination of five contracts.
- Compensation of US$6.6 million agreed for terminated contracts.
- One sales contract remains for delivery of 600,000 lbs from 2028 to 2033.
- Central Processing Plant construction is complete with ongoing commissioning.
- Dry yellowcake production expected in the September quarter.
- Keith Bowes appointed as Non-Executive Director.
- Mark Wheatley and Harrison Barker to retire from Board.
- Efforts underway to secure financing and lift trading suspension.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Peninsula Energy Limited (PEN) ORDINARY FULLY PAID |
Energy |
$223 |
Sales Contracts and Company Update
|
28 Jul 2025 10:00AM |
$0.620 |
$0.390 |
fallen by
37.10%
|
|
PEN - Price-sensitive ASX Announcement
Full Release
Key Points
- Termination of five out of six offtake contracts for US$6.6 million.
- Secured a debt facility of up to US$15 million.
- Central Processing Plant nearing completion with water commissioning underway.
- Dried yellowcake production targeted for the September quarter.
- One remaining contract for delivery of 100,000 pounds per annum from 2028 to 2033.
- Keith Bowes appointed as Non-Executive Director.
- Company's focus on securing financing for the reset plan.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| BKI Investment Company Limited (BKI) ORDINARY FULLY PAID |
Financials |
$1,441 |
BKI 25 July 2025 Weekly NTA
|
28 Jul 2025 10:00AM |
$1.820 |
$1.785 |
fallen by
1.92%
|
|
| Alterity Therapeutics Limited (ATH) ORDINARY FULLY PAID |
Health Care |
$146 |
Positive ATH434 Results from Open-Label Phase 2 Trial in MSA
|
28 Jul 2025 9:59AM |
$0.016 |
$0.670 |
risen by
4,087.50%
|
|
ATH - Price-sensitive ASX Announcement
Full Release
Key Points
- ATH434 demonstrated a favorable safety and tolerability profile in MSA patients at both 30mg and 60mg doses.
- Effective drug exposure increased predictably with the higher dose.
- A slower rate of clinical decline was observed in ATH434-treated patients versus a matched Natural History Study cohort, as measured by UMSARS.
- Stabilization of orthostatic hypotension and improvements in other MSA symptoms were reported.
- Results support continued development and a randomized, placebo-controlled Phase 2 clinical trial of ATH434 in MSA.
- ATH434 is a first-in-class small molecule designed to inhibit the accumulation and toxicity of pathological proteins implicated in neurodegenerative diseases.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| PainChek Ltd (PCK) ORDINARY FULLY PAID |
Health Care |
$21 |
Proposed issue of securities - PCK
|
28 Jul 2025 9:58AM |
$0.040 |
$0.100 |
risen by
150%
|
|
| PainChek Ltd (PCK) ORDINARY FULLY PAID |
Health Care |
$21 |
Investor Presentation
|
28 Jul 2025 9:58AM |
$0.040 |
$0.100 |
risen by
150%
|
|
| Saturn Metals Limited (STN) ORDINARY FULLY PAID |
Materials |
$276 |
Pause in Trading
|
28 Jul 2025 9:58AM |
$0.415 |
$0.505 |
risen by
21.69%
|
|
STN - Price-sensitive ASX Announcement
Full Release
Key Points
- Saturn Metals Limited (ASX: STN) requested a trading halt on 13 June 2024.
- The trading halt is due to a pending announcement concerning a capital raising.
- The company aims to manage its disclosure obligations during this period.
- Trading will remain paused until the earlier of an announcement or market open on 17 June 2024.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| PainChek Ltd (PCK) ORDINARY FULLY PAID |
Health Care |
$21 |
Strongly Supported A$7.5m Placement to Drive Int. Growth
|
28 Jul 2025 9:58AM |
$0.040 |
$0.100 |
risen by
150%
|
|
PCK - Price-sensitive ASX Announcement
Full Release
Key Points
- PainChek Ltd announced a strongly supported A$7.5 million placement.
- Placement was oversubscribed with demand from new and existing investors.
- Funds will be used for international growth, product development, and regulatory clearance.
- Focus on expanding into new and existing markets using AI-driven pain assessment technology.
- The placement supports commercialization and global market penetration strategies.
- Management highlights a robust revenue pipeline and positive market adoption.
- Board expresses gratitude for investor support and commitment to international expansion.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Larvotto Resources Limited (LRV) ORDINARY FULLY PAID |
Materials |
$660 |
Cleansing Statement
|
28 Jul 2025 9:58AM |
$0.695 |
$1.270 |
risen by
82.73%
|
|
| Larvotto Resources Limited (LRV) ORDINARY FULLY PAID |
Materials |
$660 |
Share Purchase Plan Letter and Offer Booklet
|
28 Jul 2025 9:57AM |
$0.695 |
$1.270 |
risen by
82.73%
|
|
LRV - Price-sensitive ASX Announcement
Full Release
Key Points
- Larvotto Resources Limited is conducting a Share Purchase Plan (SPP) for eligible shareholders.
- Each eligible shareholder can apply for up to $30,000 worth of new shares.
- No brokerage or transaction costs are incurred for participating shareholders.
- The SPP follows a recent institutional placement to raise additional funds.
- Funds raised will be used for exploration and development of key projects.
- The SPP Offer Booklet outlines eligibility, key dates, application process, and risks.
- Investors are advised to carefully read the SPP Booklet and consider the risks prior to participation.
- Participation in the SPP is optional and subject to eligibility criteria.
- The offer is not underwritten.
- The document includes standard disclaimers regarding investment and legal advice.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| FBR Ltd (FBR) ORDINARY FULLY PAID |
Industrials |
$21 |
FBR launches DST enabled robotic welding product Mantis
|
28 Jul 2025 9:57AM |
$0.005 |
$0.003 |
fallen by
40%
|
|
| Anax Metals Limited (ANX) ORDINARY FULLY PAID |
Materials |
$49 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
28 Jul 2025 9:57AM |
$0.007 |
$0.028 |
risen by
300%
|
|
ANX - Price-sensitive ASX Announcement
Full Release
Key Points
- Advanced Whim Creek Copper-Zinc Project permitting and agreements.
- Completed metallurgical test work to support project development.
- Continued exploration at regional tenements, including Loudens Patch and Mount Short.
- Strong focus on ESG initiatives and stakeholder engagement.
- Reported net operating cash outflows primarily from exploration and evaluation.
- Maintained a solid cash position for future project development.
- Disclosed payments to related parties in line with regulatory requirements.
- Company remains on track with project milestones and exploration activities.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Compumedics Limited (CMP) ORDINARY FULLY PAID |
Health Care |
$48 |
Business Update Asia - $24m agreements signed
|
28 Jul 2025 9:55AM |
$0.295 |
$0.240 |
fallen by
18.64%
|
|
CMP - Price-sensitive ASX Announcement
Full Release
Key Points
- Compumedics Limited signed $24 million worth of agreements in Asia.
- The agreements involve supply of medical and diagnostic equipment.
- Strategic partnerships and collaborations formed with key healthcare organizations in Asia.
- These developments are expected to enhance Compumedics’ presence in the Asian market.
- The agreements support the company’s ongoing expansion and growth strategy.
- Compumedics continues its leadership in sleep, brain diagnostics, and neurodiagnostic solutions.
- The business update emphasizes the importance of the Asian market for future revenue growth.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Emyria Limited (EMD) ORDINARY FULLY PAID |
Health Care |
$33 |
June 2025 Quarterly Activities Report and Appendix 4C
|
28 Jul 2025 9:55AM |
$0.041 |
$0.041 |
fallen by
0%
|
|
EMD - Price-sensitive ASX Announcement
Full Release
Key Points
- Update on Emyria's progress in cannabinoid-based drug development, especially EMD-RX5.
- Details on regulatory submissions and interactions with authorities for product approvals.
- Overview of strategic partnerships and collaborations to advance commercial goals.
- Financial summary including cash flow, expenditures, and corporate strategy.
- Commercial activities in Australia and potential expansion into international markets.
- Outlook for future quarters and focus areas for ongoing research and development.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
